Larimar Therapeutics Inc LRMR
$4.18 $0.02 (0.48%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
LRMR Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Larimar Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Larimar Therapeutics Inc. Stock Analysis LRMR
United States Health Care Small Cap Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing treatments for patients suffering from complex rare diseases using a novel cell penetrating peptide technology platform. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Larimar Therapeutics Inc (LRMR) Chart
Financial Metrics & Statements of Larimar Therapeutics Inc (LRMR)
FAQ's for Larimar Therapeutics Inc (LRMR)
- As of August 2026, Larimar Therapeutics Inc LRMR is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Larimar Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Larimar Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Larimar Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Larimar Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Larimar Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Larimar Therapeutics Inc (LRMR)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
